A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC

INTRODUCTION: The use of immune checkpoint inhibitors (ICIs) with chemotherapy has increased the survival of patients with advanced NSCLC. Nevertheless, the efficacy of ICI treatment for NSCLC with EGFR mutations is limited. Previous studies have not evaluated the efficacy of ICI treatment after osi...

Descripción completa

Detalles Bibliográficos
Autores principales: Morimoto, Kenji, Sawada, Ryo, Yamada, Tadaaki, Azuma, Koichi, Ito, Kentaro, Goto, Yasuhiro, Kimura, Hideharu, Harada, Taishi, Shiotsu, Shinsuke, Tamiya, Nobuyo, Chihara, Yusuke, Takeda, Takayuki, Hiranuma, Osamu, Hasegawa, Isao, Morimoto, Yoshie, Iwasaku, Masahiro, Tokuda, Shinsaku, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445370/
https://www.ncbi.nlm.nih.gov/pubmed/36082280
http://dx.doi.org/10.1016/j.jtocrr.2022.100388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445370/
https://www.ncbi.nlm.nih.gov/pubmed/36082280
http://dx.doi.org/10.1016/j.jtocrr.2022.100388

Ejemplares similares